Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Development programme

MariTide — maridebart cafraglutide

The programme for a GIP receptor antagonist and GLP-1 receptor agonist antibody–peptide conjugate administered monthly or less frequently.

The programme for a GIP receptor antagonist and GLP-1 receptor agonist antibody–peptide conjugate administered monthly or less frequently.

Sponsor class: Manufacturer-sponsored. First record: 2021.

Showing 0 records on this page

Records in this programme

10 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
MARITIDE-PH2-OBESITYMaridebart cafraglutidePhase 2ReportedRandomised, double-blind, placebo-controlled5922024Low
MARITIDE-PH2-T2DMaridebart cafraglutidePhase 2ReportedRandomised, double-blind, placebo-controlled—2024Low
MARITIDE-PH3Maridebart cafraglutidePhase 3OngoingRandomised, double-blind, placebo-controlled——Not rated
MARITIDE-PH2-OBESITY-HEPATIC-IMPprogramme recordMaridebart cafraglutidePhase 1ReportedPhase 1 ascending dose—2024Very low
MARITIDE-PH2-T2D-BODY-COMPprogramme recordMaridebart cafraglutidePhase 2ReportedRandomised, double-blind, placebo-controlled—2024Very low
MARITIDE-PH2-T2D-REGIONAL-CNprogramme recordMaridebart cafraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
MARITIDE-PH2-T2D-REGIONAL-JPprogramme recordMaridebart cafraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
MARITIDE-PH3-BIOMARKERprogramme recordMaridebart cafraglutidePhase 3OngoingRandomised, double-blind, placebo-controlled——Very low
MARITIDE-PH3-HEPATIC-IMPprogramme recordMaridebart cafraglutidePhase 1OngoingPhase 1 ascending dose——Very low
MARITIDE-PH3-RENAL-IMPprogramme recordMaridebart cafraglutidePhase 1OngoingPhase 1 ascending dose——Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.